Division of Pulmonary and Critical Care Medicine and the Cardiovascular Research Institute, Room 1307, Health Sciences East, 513 Parnassus Avenue, San Francisco, California 94143, USA.
- John V. Fahy
Competing interests statement
The author is a named inventor on a patent application for periostin as a biomarker in asthma. He has consulted for Amgen, Merck, Regeneron, Boehringer Ingelheim and MedImmune.
John V. Fahy
John V. Fahy studied for his M.D. at University College Dublin, Dublin, Ireland, and his M.Sc. at Trinity College Dublin. He trained in internal medicine programmes in Ireland, and in pulmonary and critical care medicine at the University of California, San Francisco (UCSF), USA. He remains at UCSF as Professor of Medicine, where he directs the UCSF Airway Clinical Research Center and the outpatient programme in severe asthma. His research programme focuses on epithelial cell dysfunction in airway disease and on studies of disease endotypes in asthma. John V. Fahy's laboratory homepage.
- Asthma control questionnaire
A tool for measuring quality of life and symptoms in patients with asthma. It assesses whether an individual wakes in the mornings with symptoms, the limitations of daily activities, shortness of breath and wheeze.
A tendency to develop IgE-mediated allergic disease, such as asthma, eczema (atopic dermatitis), allergic rhinitis (hay fever) or allergic conjunctivitis.
- Bronchial hyperresponsiveness
(BHR). A state in which the airways are hyperreactive to various bronchoconstrictor stimuli, including methacholine, histamine, hypertonic saline, distilled water, exercise or eucapnic hyperventilation. Hyperresponsiveness in this context means a bronchoconstrictor response at 'doses' that normally have no bronchoconstrictor effect.
(Forced expired volume in 1 second). A measure of airflow. Decreases in FEV1 are characteristic of asthma and are one metric of asthma severity.
Steroid hormones that are produced in the adrenal glands. Synthetic analogues are available as anti-inflammatory drugs that are particularly effective in suppressing type 2 immune responses.
- Group 2 innate lymphoid cells
(ILC2s). ILC2s are a subtype of innate lymphoid cells, which are a novel family of haematopoietic effector cells with heterogeneous location, cytokine production and effector functions. ILC2s specifically produce type 2 cytokines and depend on GATA-binding protein 3 and retinoic acid receptor-related orphan receptor-α for their development and function.
(Severe Asthma Research Program). A network of seven asthma research centres and one data coordination centre in the United States. SARP aims to improve understanding of the heterogeneity of asthma, including asthma endotypes, with the ultimate goal of better treatments. It is funded by the US National Heart, Lung and Blood Institute.
(Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes). A European-wide project that aims to uncover biomarkers of asthma and to identify mechanisms of disease subtypes to improve the treatment of asthma. It is funded by the Innovative Medicine Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).